Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq
- PMID: 30383866
- PMCID: PMC6211742
- DOI: 10.1371/journal.pone.0206785
Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq
Erratum in
-
Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.PLoS One. 2018 Dec 4;13(12):e0208778. doi: 10.1371/journal.pone.0208778. eCollection 2018. PLoS One. 2018. PMID: 30513122 Free PMC article.
Abstract
Here we investigated different cell populations within ovarian cancer using single-cell RNA seq: fourteen samples from nine patients with differing grades (high grade, low grade and benign) as well as different origin sites (primary and metastatic tumor site, ovarian in origin and fallopian in origin). We were able to identify sixteen distinct cell populations with specific cells correlated to high grade tumors, low grade tumors, benign and one population unique to a patient with a breast cancer relapse. Furthermore the proportion of these populations changes from primary to metastatic in a shift from mainly epithelial cells to leukocytes with few cancer epithelial cells in the metastases. Differential gene expression shows myeloid lineage cells are the primary cell group expressing soluble factors in primary samples while fibroblasts do so in metastatic samples. The leukocytes that were captured did not seem to be suppressed through known pro-tumor cytokines from any of the cell populations. Single cell RNA-seq is necessary to de-tangle cellular heterogeneity for better understanding of ovarian cancer progression.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21: 750–755. 10.1097/IGC.0b013e31821b2568 - DOI - PubMed
-
- Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143: 3–15. 10.1016/j.ygyno.2016.05.022 - DOI - PMC - PubMed
-
- Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen L-M, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14: 1134–1163. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
